Onco-nephrology: The pathophysiology and treatment of malignancy-associated hypercalcemia

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 10, 2012, Pages 1722-1729

  Rosner, Mitchell H ^a   Dalkin, Alan C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; DENOSUMAB; FUROSEMIDE; GALLIUM NITRATE; IBANDRONIC ACID; LOOP DIURETIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; SODIUM CHLORIDE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST ADENOCARCINOMA; CALCIUM BLOOD LEVEL; CANCER INVASION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANCY ASSOCIATED HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; OVARY ADENOCARCINOMA; PATHOPHYSIOLOGY; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA;

HUMANS; HYPERCALCEMIA; MEDICAL ONCOLOGY; NEOPLASMS; NEPHROLOGY; OSTEOLYSIS; PARANEOPLASTIC SYNDROMES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84867276972     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02470312     Document Type: Article

References (92)

1. Sargent JTS, Smith OP: Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol 149: 465-477, 2010
2. Stewart AF: Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352: 373-379, 2005
3. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT: Cancerassociated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann InternMed 112: 499-504, 1990
4. Burt ME, Brennan MF: Incidence of hypercalcemia and malignant neoplasm. Arch Surg 115: 704-707, 1980
5. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF: Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71: 1309-1312, 1993
6. Edelson GW, Kleerekoper M: Hypercalcemic crisis. Med Clin North Am 79: 79-92, 1995
7. Labriola L, Wallemacq P, Gulbis B, Jadoul M: The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant 24: 1834-1838, 2009
8. Ijaz A, Mehmood T, Qureshi AH, Anwar M, Dilawar M, Hussain I, Khan FA, Khan DA, Hussain S, Khan IA: Estimation of ionized calcium, total calcium and albumin corrected calcium for the diagnosis of hypercalcaemia of malignancy. J Coll Physicians Surg Pak 16: 49-52, 2006
9. Riancho JA, Arjona R, Sanz J, Olmos JM, Valle R, Barceló JR, González-Macías J: Is the routine measurement of ionized calcium worthwhile in patients with cancer? Postgrad Med J 67: 350-353, 1991
10. Mellis DJ, Itzstein C, Helfrich MH, Crockett JC: The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol 211: 131-143, 2011
11. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999
12. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490-495, 2004
13. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221-1230, 2003
14. Abou-Samra AB, Jüppner H, Force T, Freeman MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT Jr, et al: Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 89: 2732-2736, 1992
15. Sone S, Yano S: Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev 26: 685-689, 2007
16. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ: Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73: 1309-1315, 1991
17. Sourbier C, Massfelder T: Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 240: 170-182, 2006
18. Yoshimoto K, Yamasaki R, Sakai H, Tezuka U, Takahashi M, Iizuka M, Sekiya T, Saito S: Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 68: 976-981, 1989
19. Iguchi H, Miyagi C, Tomita K, Kawauchi S, Nozuka Y, Tsuneyoshi M, Wakasugi H: Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland. J Clin EndocrinolMetab 83: 2653-2657, 1998
20. Nussbaum SR, Gaz RD, Arnold A: Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323: 1324-1328, 1990
21. Chen YC, Sosnoski DM, Mastro AM: Breast cancer metastasis to the bone: Mechanisms of bone loss. Breast Cancer Res 12: 215-226, 2010
22. Clines GA: Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol DiabetesObes 18: 339-346, 2011
23. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L: Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89: 567-577, 2004
24. Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F: Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 76: 801-803, 1993
25. Seymour JF, Gagel RF: Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82: 1383-1394, 1993
26. Hatake K, Uwai M, Ohtsuki T, Tomizuka H, Izumi T, Yoshida M, Miura Y: Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol 66: 13-19, 1997
27. Castelli I, Steiner LA, Kaufmann MA, Drop LJ: Renovascular responses to high and low perfusate calcium steady-state experiments in the isolated perfused rat kidney with baseline vascular tone. J Surg Res 61: 51-57, 1996
28. Hebert SC, Brown EM: The scent of an ion: Calcium-sensing and its roles in health and disease. Curr Opin Nephrol Hypertens 5: 45-53, 1996
29. Khanna A: Acquired nephrogenic diabetes insipidus. Semin Nephrol 26: 244-248, 2006
30. Sleeboom HP, bijvoet OLM, Van Oosterom AT, Gleed JH, O'Riordan JL: Comparison of intravenous (3-amino-1-hydroxypropylidene)-1-1-bisphosphonate and volume repletion in tumour-induced hypercalcemia. Lancet 2: 239-243, 1983
31. Kacprowicz RF, Lloyd JD: Electrolyte complications of malignancy. Hematol Oncol Clin North Am 24: 553-565, 2010
32. LeGrand SB, Leskuski D, Zama I: Narrative review: Furosemide for hypercalcemia: An unproven yet common practice. Ann Intern Med 149: 259-263, 2008
33. Nielsen SP, Andersen O, Steven KE: Magnesium and calcium metabolism during prolonged furosemide (Lasix) administration to normal rats. Acta Pharmacol Toxicol (Copenh) 27: 469-479, 1969
34. Toft H, Roin J: Effect of frusemide administration on calcium excretion. BMJ 1: 437-438, 1971
35. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 74: 1385-1393, 2008
36. Lin JH: Bisphosphonates: A review of their pharmacokinetic properties. Bone 18: 75-85, 1996
37. Russell RGG, Rogers MJ: Bisphosphonates: From the laboratory to the clinic and back again. Bone 25: 97-106, 1999
38. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 1657-1663, 1992
39. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88[Suppl]: 2961-2978, 2000
40. Hiroi-Furuya E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamaru Y, Watanabe-Mano M, Okuda N, Shimada J, Yamamoto Y, Hakeda Y, Kumegawa M: Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 64: 219-223, 1999
41. Mackie PS, Fisher JL, Zhou H, Choong PF: Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84: 951-958, 2001
42. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72: 1289-1293, 1995
43. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J: A dosefinding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14: 1557-1561, 1999
44. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14: 268-276, 1996
45. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE: Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 95: 297-304, 1993
46. Dodwell DJ, Howell A, Morton AR, Daley-Yates PT, Hoggarth CR: Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 68: 434-439, 1992
47. Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate in tumor-induced hypercalcemia. Lancet 341: 1611-1613, 1993
48. Walls J, Ratcliffe WA, Howell A, Bundred NJ: Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 70: 169-172, 1994
49. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001
50. Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergström B: Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate. Support Care Cancer 11: 539-547, 2003
51. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21: 389-406, 1999
52. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD: Collapsing focal segmental glomerulosclerosis following treatment with highdose pamidronate. J Am Soc Nephrol 12: 1164-1172, 2001
53. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, Walker PD: Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65: 634-641, 2004
54. Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Li ZJ, Jagannath S: Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119: 496-499, 2002
55. Markowitz GS, Fine PL, D'agati VD: Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39: 1118-1122, 2002
56. Bodmer M, Amico P, Mihatsch MJ, Haschke M, Kummer O, Krähenbühl S, Mayr M: Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Dial Transplant 22: 2366-2370, 2007
57. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281-289, 2003
58. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7: 377-387, 2001
59. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150-3157, 2003
60. Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676-1679, discussion 1676-1679, 2003
61. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K; American Society of Clinical Oncology: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464-2472, 2007
62. Heidenreich A, Elert A, Hofmann R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5: 231-235, 2002
63. Body JJ, Diel IJ, Tripathy D, Bergstrom B: Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases frombreast cancer: Phase III trial results. Eur J Cancer Care (Engl) 15: 299-302, 2006
64. Bergner R, Henrich DM, Hoffmann M, et al: Renal safety of ibandronate in multiple myeloma patients with renal deterioration. Cancer Treat Rev 31[suppl 1]: S45, 2005
65. Carter GD, Goss AN: Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48: 268, 2003
66. Hellstein JW, Kalmar JR: For the dental patient. Osteoporosis medications and the risk of developing jaw complications. J Am Dent Assoc 138: 692, 2007
67. Carneiro E, Vibhute P, Montazem A, Som PM: Bisphosphonate associated mandibular osteonecrosis. AJNR Am J Neuroradiol 27: 1096-1097, 2006
68. American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J AmDent Assoc 137: 1144-1150, 2006
69. Repo MA, Bockman RS, Betts F, Boskey AL, Alcock NW, Warrell RP Jr: Effect of gallium on bone mineral properties. Calcif Tissue Int 43: 300-306, 1988
70. Bockman RS: Studies on the mechanism of action of gallium nitrate. Semin Oncol 18[Suppl 5]: 21-25, 1991
71. Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M, Staszewski H: Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73: 1487-1490, 1984
72. Hall TJ, Chambers TJ: Gallium inhibits bone resorption by a direct effect on osteoclasts. Bone Miner 8: 211-216, 1990
73. Cvitkovic F, Armand J-P, Tubiana-Hulin M, Rossi JF, Warrell RP Jr: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12: 47-53, 2006
74. Warrell RP Jr, Murphy WK, Schulman P, O'Dwyer PJ, Heller G: A randomized double-blind study of galliumnitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 9: 1467-1475, 1991
75. Warrell RP Jr, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med 108: 669-674, 1988
76. Huang CL, Sun L, Moonga BS, Zaidi M: Molecular physiology and pharmacology of calcitonin. Cell Mol Biol (Noisy-le-grand) 52: 33-43, 2006
77. Purdue BW, Tilakaratne N, Sexton PM: Molecular pharmacology of the calcitonin receptor. Receptors Channels 8: 243-255, 2002
78. Davidson TG: Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm 58[Suppl 3]: S8-S15, 2001
79. Mathur M, Sykes JA, Saxena VR, et al: Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin. Pediatr Crit Care Med 4: 252-255, 2003
80. Bilezikian JP: Management of acute hypercalcemia. NEngl J Med 326: 1196-1203, 1992
81. Santarpia L, Koch CA, Sarlis NJ: Hypercalcemia in cancer patients: Pathobiology and management. Horm Metab Res 42: 153-164, 2010
82. Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 43: 630-640, 1993
83. Srámek V, Novák I, Matějovic M, Rokyta R, Nalos M, Hora P, Pittrová H: Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. Intensive Care Med 24: 262-264, 1998
84. Kindgen-Milles D, Kram R, Kleinekofort W, Morgera S: Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation. ASAIO J 54: 442-444, 2008
85. Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H: The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 16: 136-145, 2011
86. Background document for meeting of advisory committee for reproductive health drugs. FDA report, August 13, 2009. Available at http://www.fda.gov. Accessed 2/29/2012
87. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23: 1341-1347, 2012
88. Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139, 2010
89. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125-1132, 2011
90. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377: 813-822, 2011
91. Hu MI, Gucalp R, Insogna K, et al: Denosumab for treatment of hypercalcemia of malignancy in patients with solid tumors or hematological malignancies refractory to IV bisphosphonates: a single-arm multicenter study. Presented at the 53rd American Society of Henatology Annual Meeting and Exposition, San Diego, CA, December 10-13, Abstract 2483
92. Diel IJ, Body J-J, Stopeck A, et al: Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011